873198--4/16/2008--GUARDIAN_TECHNOLOGIES_INTERNATIONAL_INC

related topics
{stock, price, share}
{product, candidate, development}
{regulation, government, change}
{product, liability, claim}
{control, financial, internal}
{operation, international, foreign}
{product, market, service}
{interest, director, officer}
{property, intellectual, protect}
{stock, price, operating}
{personnel, key, retain}
{customer, product, revenue}
{debt, indebtedness, cash}
{acquisition, growth, future}
{provision, law, control}
Risks Related to Our Company and Our Operations Our business plan and technologies are unproven. We have generated minimal revenues from our operation, and incurred substantial operating losses since our inception. We have very limited cash resources. We have a severe working capital deficit and, in addition to proceeds from financings, we continue to have outstanding loans from our chief executive officer and deferrals of salaries by our executive officers and a consultant to indirectly continue to fund operations. Dilutive effect of conversion of Series A 10% Senior Convertible Debentures and exercise of Series D Warrants and Midtown placement agent s warrants. We have incurred substantial debt which could affect our ability to obtain additional financing and may increase our vulnerability to business downturns. Additionally, as disclosed below, we may be in default under the debenture agreements. We did not make certain interest payments due under our Series A Debentures and may be deemed to be in default. Also, we may be deemed to be in non-compliance with a negative covenant under the debentures. Our certifying officers evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2005, as of March 31, 2006, June 30, 2006, September 30, 2006, December 31, 2006, September 30, 2007, and December 31, 2007, and concluded that our disclosure controls were not effective and that we had certain weaknesses in our internal controls over timely reporting. Current shareholdings may be diluted if we make future equity issuances or if outstanding debentures, warrants, and options are exercised for or converted into shares of common stock. We may face competition from other developers or sellers of imaging and radiology technology and baggage screening technology. We may undertake acquisitions which pose risks to our business. Our independent registered public accounting firm has expressed uncertainty regarding our ability to continue as a going concern. Investor confidence in the price of our stock may be adversely affected if we are unable to comply with Section 404 of the Sarbanes-Oxley Act of 2002. In order to comply with public reporting requirements, we must continue to strengthen our financial systems and controls, and failure to do so could adversely affect our ability to provide timely and accurate financial statements. In preparing our consolidated financial statements, we identified material weaknesses in our internal control over financial reporting, and our failure to remedy effectively the material weaknesses identified as of December 31, 2007 could result in material misstatements in our financial statements and investors could lose confidence in our financial reports, and our stock price may be adversely affected. Our stock price is volatile. There is a limited market for our common stock. Because we became public because of a reverse acquisition, we may not be able to attract the attention of major brokerage firms or institutional investors. Our common stock is subject to the SEC s Penny Stock Regulations. Certain provisions of our charter and bylaws may discourage mergers and other transactions. Our board of directors may issue additional shares of preferred stock without stockholder approval. We depend on key personnel. Our directors and named executive officers own a substantial percentage of our common stock. Our ability to attract and retain additional skilled personnel may impact our ability to develop our technology and attract customers in growing our business. We have never paid a cash dividend Risks Related to Our Industries Changes may take place in funding for healthcare. Virtually all of our prospective customers in the healthcare industry are subject to governmental regulation, including Medicare and Medicaid regulation. Product liability claims may occur. Specific government regulations relating to Medicare and Medicaid may impinge on us. Medical device regulation may require us to obtain approval for our products. System errors and warranties may subject us to liability. We may infringe the proprietary rights of others. Unforeseeable disruption in the economy may take place consequent to terrorism or other international events. A number of factors that affect our revenues make our future results difficult to predict, and therefore we may not meet expectations for a particular period. We expect to depend on a small number of customers for a substantial portion of our future revenues. Governmental agencies, the primary customers for our PinPoint products, are subject to budget processes which could limit the demand for these products. Legislative actions could lead to fluctuations in demand for transportation security scanning products and services. Governmental agencies have special contracting requirements, which create additional risks. Our growth depends on our introduction of new products and services, which may be costly to develop and may not achieve market acceptance. Our PinPoint product may fail to obtain certification by the TSA. Our existing PinPoint product may fail to obtain re-certification by the TSA for changes in the PinPoint system. Our major potential customer, the TSA, is a part of the Department of Homeland Security, a newly created agency that has experienced, and may continue to experience, delays in its operations, which may cause delays in our receiving orders for our products from the TSA. Future sales of our PinPoint products will depend on the ability of airports to secure funding to build baggage handling systems and to integrate our PinPoint product into such systems, which they may not be able to do. If our PinPoint product fails to detect explosives, we could be exposed to product liability and related claims for which we may not have adequate insurance coverage, and we may lose current and potential customers. We expect to substantially depend on large orders from a limited number of customers. As a result, order cancellations from any of our customers or the failure of these customers to continue to purchase PinPoint products could have a material negative impact on our business and financial results. The sales cycle for our PinPoint products is lengthy and we may expend a significant amount of effort in obtaining sales orders and not receive them. Our future international sales subject us to risks that could materially harm our business. Exchange rate fluctuations could cause a decline in our financial condition and results of operations. Our inability to adapt to rapid technological change could impair our ability to remain competitive. The transportation security scanning industry is highly competitive. Given the anticipated continuing demand for airport security products, competition may increase. We are reliant upon third party distributors for the distribution and licensing of our PinPoint or Signature Mapping products in several domestic or foreign jurisdictions and have reduced our reliance upon our own internal sales force. Litigation may be necessary to enforce or defend against claims of intellectual property infringement, which could be expensive and, if we lose, could prevent us from selling our products.

Full 10-K form ▸

related documents
873198--3/29/2007--GUARDIAN_TECHNOLOGIES_INTERNATIONAL_INC
1018354--4/14/2008--NEW_YORK_HEALTH_CARE_INC
1018354--4/19/2007--NEW_YORK_HEALTH_CARE_INC
873198--5/16/2006--GUARDIAN_TECHNOLOGIES_INTERNATIONAL_INC
357097--4/15/2009--ISOLAGEN_INC
1036968--8/30/2007--VAXGEN_INC
911216--9/28/2009--PALATIN_TECHNOLOGIES_INC
1360214--3/31/2010--TRANSDEL_PHARMACEUTICALS_INC
1364326--1/5/2010--Pure_Pharmaceuticals_CORP
1159036--3/13/2009--HALOZYME_THERAPEUTICS_INC
1314102--9/25/2009--pSivida_Corp.
1328003--3/29/2010--Redpoint_Bio_CORP
1424768--3/31/2010--VYCOR_MEDICAL_INC
727510--3/12/2010--ENZON_PHARMACEUTICALS_INC
1057377--4/14/2008--SAMARITAN_PHARMACEUTICALS_INC
1200528--12/15/2008--EN2GO_INTERNATIONAL_INC
1100644--4/15/2010--VALIDIAN_CORP
1479426--9/30/2010--DynaVox_Inc.
1172480--3/4/2008--SANTARUS_INC
855182--5/28/2008--IBIS_TECHNOLOGY_CORP
1360214--3/26/2009--TRANSDEL_PHARMACEUTICALS_INC
1427222--3/31/2010--WELLQUEST_MEDICAL_&_WELLNESS_CORP
1019034--3/11/2009--BIO_KEY_INTERNATIONAL_INC
1383183--3/27/2009--CombiMatrix_Corp
1030839--2/5/2009--Synovics_Pharmaceuticals
1318310--2/25/2010--ev3_Inc.
1383183--3/18/2010--CombiMatrix_Corp
1311318--4/1/2008--Lightspace_Corp
3116--3/16/2010--AKORN_INC
1003642--3/12/2009--IMPAX_LABORATORIES_INC